Nyxoah Reports Third Quarter 2023 Financial and Operating Results 9-11-2023, 04:05

Brandon Hall Group Launches Study on Evolution of Skills 13-02-2023, 22:03

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection 22-10-2024, 19:00